Dishman Carbogen Amcis Limited

DCAL

INE385W01011

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 04:35:03 13/03/2026 pm IST			5-day change	1st Jan Change
158.95 ^INR	-3.79%		-3.22%	-35.80%

05/02	Dishman Carbogen Amcis Limited, Q3 2026 Earnings Call, Feb 04, 2026
03/02	Dishman Carbogen Amcis Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI

Dishman Carbogen's Shanghai Unit Gets Drug Manufacturing License

Published on 04/10/2025 at 10:25 am IST - Modified on 04/10/2025 at 10:26 am IST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Dishman Carbogen Amcis Limited

05/02	Dishman Carbogen Amcis Limited, Q3 2026 Earnings Call, Feb 04, 2026
03/02	Dishman Carbogen Amcis Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
03/02	Dishman Carbogen Amcis Dec-quarter Consol Net Loss After Tax 129.7 Million Rupees	RE
27/12	Dishman Carbogen Amcis Limited Approves Issue of Senior, Secured, Rated, Listed, Transferable, Taxable, Redeemable Non-Convertible Debentures Aggregating Up to INR 500 Million	CI
23/12	Dishman Carbogen Amcis to consider fund raising via NCDs	RE
05/11	Dishman Carbogen Amcis Limited, Q2 2026 Earnings Call, Nov 05, 2025
04/11	Dishman Carbogen Amcis Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
26/25/26	Dishman Carbogen Amcis receives EIR from US FDA indicating inspection closure	RE
13/25/13	Dishman Carbogen Amcis Limited, Q1 2026 Earnings Call, Aug 13, 2025
13/25/13	Dishman Carbogen Amcis Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI
27/25/27	Dishman Carbogen Amcis Limited Announces the Demise of Shri Janmejay R. Vyas, Chairman & Non-Executive Director on May 27, 2025	CI
22/25/22	Dishman Carbogen Amcis Limited, Q4 2025 Earnings Call, May 22, 2025
22/25/22	Dishman Carbogen Amcis Limited Reports Earnings Results for the Full Year Ended March 31, 2025	CI
21/25/21	Dishman Carbogen Amcis Says Subsidiary Awarded Drug Manufacturing License From Chinese NMPA	RE
10/25/10	Dishman Carbogen's Shanghai Unit Gets Drug Manufacturing License	MT

Chart Dishman Carbogen Amcis Limited

Duration

Period

DCAL: Dynamic Chart

Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS), quats, specialty chemicals, Vitamins D3 and its analogues, cholesterols, and disinfectants. The Companyâ€™s segments include CRAMS and Marketable Molecules. The CRAMS segment includes Contract Research Services and Contract Manufacturing Services, which it offers to its customers. Through its CRAMS business, the Company assists drug manufacturers in the development and optimization of processes for novel drug molecules in various stages of the development process. Its Marketable Molecules segment manufactures and supplies intermediates, chemicals, and various products for pharmaceutical, cosmetic and related industries. It has manufacturing and research facilities in India, Switzerland, France, the Netherlands, the United Kingdom and China. Its subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd. and Dishman Carbogen Amcis (Singapore) Pte. Ltd.

Employees

1,106

Sector

Pharmaceuticals

More about the company